Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of “Buy” by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has received an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.00.

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st.

Aura Biosciences Price Performance

Shares of AURA stock opened at $7.35 on Monday. The company has a market cap of $367.14 million, a price-to-earnings ratio of -4.25 and a beta of 0.30. The stock has a 50 day simple moving average of $7.70 and a 200-day simple moving average of $8.68. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 23,045 shares of company stock worth $177,242. 5.40% of the stock is owned by corporate insiders.

Institutional Trading of Aura Biosciences

Several large investors have recently made changes to their positions in AURA. Long Focus Capital Management LLC grew its holdings in Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after buying an additional 1,404,228 shares in the last quarter. Vanguard Group Inc. grew its holdings in Aura Biosciences by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock valued at $15,764,000 after buying an additional 112,296 shares in the last quarter. Franklin Resources Inc. grew its holdings in Aura Biosciences by 3.2% in the 4th quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock valued at $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after buying an additional 783,984 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Aura Biosciences by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after buying an additional 3,972 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.